Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
about
Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysisEssential role of protein kinase G and decreased cytoplasmic Ca2+ levels in NO-induced inhibition of rat aortic smooth muscle cell motilityReview: Clinical aspects of vascular remodeling.Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.Novel approaches for the prevention of restenosis.Current approaches to therapy for vascular injury.Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stentingEmerging drugs for hyperlipidemia.Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature.Reactive oxygen species in cardiovascular disease.Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention?Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.Vascular protectants for the treatment of atherosclerosis.The drug-based pipeline against restenosis.Pharmacological treatment for prevention of restenosis.Oxidative stress induces early-onset apoptosis of vascular smooth muscle cells and neointima formation in response to injury.AGI-1067: a novel vascular protectant for prevention of restenosis.Antioxidants: the good, the bad and the uglyAnti-atherosclerotic and anti-diabetic properties of probucol and related compounds.Antioxidants and cardiovascular disease: Still a topic of interestPharmacological inhibition of coronary restenosis: systemic and local approaches.An antioxidant, probucol, induces anti-angiogenesis and apoptosis in athymic nude mouse xenografted human head and neck squamous carcinoma cells.The Jeremiah Metzger Lecture. Pathogenesis of atherosclerosis: redox as a unifying mechanism.Bilirubin coating attenuates the inflammatory response to everolimus-coated stents.Development of a probucol-releasing antithrombogenic drug eluting stent.Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017Targeted Treatments for Restenosis and Vein Graft Disease
P2860
Q28546595-13CF4DFC-B0FC-4EB0-98F2-4B56EA79F808Q28582613-4AC3B258-74A5-4332-85D7-D08D0BADE197Q33691209-09B83E27-81F4-4E6F-A9D9-0E349BB64179Q33776230-409410B1-2489-48E6-B529-F45403DAAEBCQ34075160-41AABEC7-90B9-47DC-AEE0-E892C079716DQ34241012-49355F75-EF17-4985-9E70-617EFD9A8369Q34282749-D306F777-5343-4803-B083-DB984161DD4FQ34619115-2EC3674F-53CE-44E9-92A1-657219FB3FE6Q34733613-F746F075-B15F-4D94-B35A-261D9E76B4EBQ35165194-1B2D7115-6599-43DF-8862-52AEA15EE509Q35167634-A5B7A50D-1C71-4B64-848E-7B47AA1EFC0EQ35570967-1419A873-BF43-470D-AC66-E689EFE518FFQ35696297-520B1856-81D3-4309-ACA7-A3FD25718E4AQ36066019-2B234896-D21D-433F-AC2D-EF76626F161CQ36179679-D04F5F54-65D2-4ADC-AA22-2D3A8FA680D6Q36185192-514C73E0-0575-4354-94C4-66CCC71AE55BQ36320035-5A64D011-328D-4400-A55A-7D50380FDC3EQ36405142-2ABD5792-041F-491F-A7D2-43993367FE8BQ37109628-1B2165C8-2324-4B48-B6EE-7FF516DD573CQ37296652-2350EA5F-7D0D-487D-999C-2E278720E2B3Q38241974-332FA917-5053-4785-88A2-1546E2DE6568Q40908419-917E1E23-1FB0-44B2-BB40-37DEADAC48CFQ42945503-EA01A06B-2FDA-42E5-A30D-86E688C9C057Q47943695-618F5278-460F-4416-967A-02B5B55C0F23Q53387747-209E2A7E-C562-46C8-AB5A-167FA16114FDQ58362346-451ED795-3CEF-4A13-9E29-38EA44365472Q58691736-6A01D043-C4F3-40C3-A1CE-9EA97BEA4FD4
P2860
Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Effectiveness of an antioxidan ...... Angioplasty Restenosis Trial.
@en
Effectiveness of an antioxidan ...... Angioplasty Restenosis Trial.
@nl
type
label
Effectiveness of an antioxidan ...... Angioplasty Restenosis Trial.
@en
Effectiveness of an antioxidan ...... Angioplasty Restenosis Trial.
@nl
prefLabel
Effectiveness of an antioxidan ...... Angioplasty Restenosis Trial.
@en
Effectiveness of an antioxidan ...... Angioplasty Restenosis Trial.
@nl
P2093
P1476
Effectiveness of an antioxidan ...... Angioplasty Restenosis Trial.
@en
P2093
Kuwabara Y
Nishikawa H
Nishimura S
Nishiyama S
P304
P356
10.1016/S0735-1097(97)00270-2
P407
P577
1997-10-01T00:00:00Z